T1	Participants 168 191	Children's Cancer Group
T2	Participants 92 148	patients with standard-risk acute lymphoblastic leukemia
T3	Participants 219 265	childhood acute lymphoblastic leukemia (ALL) i
T4	Participants 505 548	randomized trial of more than 1000 subjects
T5	Participants 618 671	Children with National Cancer Institute standard-risk
T6	Participants 1126 1210	all patients received a dexamethasone dosage of 10 mg/m(2)/d for 21 days, with taper
T7	Participants 1296 1347	Patients randomly assigned to receive dexamethasone
